Assembling the evidence…
Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are intimately associated with inflammation and overproduction of reactive oxygen species (ROS). Temporal and inter-individual variabilities in disease activity and response to therapy pose significant challenges to diagnosis and patient care. Discovery and validation of truly integrative biomarkers would benefit from embracing redox metabolomics approaches with prioritization of central regulatory hubs. We here make a case for applying a personalized redox medicine approach that aims to selectively inhibit pathological overproduction and/or altered expression of specific enzymatic sources of ROS without compromising physiological function. To this end, improved 'clinical-omics integration' may help to better understand which particular redox signaling pathways are disrupted in what patient. Pharmacological interventions capable of activating endogenous antioxidant defense systems may represent viable therapeutic options to restore local/systemic redox status, with HIF-1α and NRF2 holding particular promise in this context. Achieving the implementation of clinically meaningful mechanism-based biomarkers requires development of easy-to-use, robust and cost-effective tools for secure diagnosis and monitoring of treatment efficacy. Ultimately, matching redox-directed pharmacological interventions to individual patient phenotypes using predictive biomarkers may offer new opportunities to break the therapeutic ceiling in IBD.
Key claims could not be produced for this evaluation. The rest of the evaluation is unaffected.
Strengths
The review discusses failed antioxidant trials, opposing HIF-1/HIF-2 effects, NRF2 hormesis, PHD isoform complexity, and the terminated GB004 phase 2 study. These qualifications materially inform the therapeutic argument rather than appearing as isolated caveats.
↳ Sections 2.2–2.3 and 4.1–4.2
Section 5 states that tangible redox metabolomics and concrete clinical examples do not yet exist, then recommends beginning with robust, cost-effective tools and independent biomarker validation.
↳ Section 5
The paper connects IBD heterogeneity and inadequate biomarkers to patient stratification, treatment selection, and monitoring, while identifying clinicians, biomarker programs, and therapeutic developers as plausible users.
↳ Abstract; Sections 1 and 5
Limitations
Although the author-contribution statement refers to an extensive literature review, the manuscript gives no search strategy, inclusion criteria, literature window, or source-selection rationale. Readers therefore cannot assess the representativeness of the synthesis.
↳ Entire manuscript; author-contribution statement
The personalized-redox argument combines established RSI, systems-biology, HIF-1α, and NRF2/KEAP1 concepts without resolving a contested empirical question. Its contribution is principally IBD-specific integration and agenda setting.
↳ Sections 2.4, 3, 4, and 5
The proposed redox-metabolomics platform and concrete personalized applications do not yet exist, while the highlighted GB004 phase 2 program was terminated for suggested lack of benefit. Several further validation and development stages are required.
↳ Sections 4.1 and 5
The review earns its strongest marks for a coherent structure and for engaging evidence that complicates its preferred therapeutic pathways. Section 5 meaningfully acknowledges the absence of a tangible redox-metabolomics platform and proposes staged development rather than immediate clinical deployment. The quality score is constrained by the lack of any reported source-selection method and by the incremental nature of the conceptual synthesis. Impact potential is moderate-to-low because identifiable clinical needs and stakeholders are offset by undeveloped biomarker tools and mixed early clinical evidence.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.3
The paper integrates the Reactive Species Interactome with HIF-1α, NRF2/KEAP1, and IBD personalization, creating a useful but incremental synthesis. The underlying framework and much of the mechanistic case substantially predate this review.
“The RSI with all its different constituents may provide the conceptual framework to develop such redox-based approaches.”
The narrative progresses coherently from redox pathophysiology through biomarkers and therapeutic targets to implementation, while engaging negative and complicating evidence. Its coverage cannot be independently appraised because no literature-search or source-selection method is reported.
“ARB, AGP and DK performed extensive literature review.”
The argument is organized by informative sections and uses modal language that generally matches the early evidence base. Dense mechanistic passages and the recurring “therapeutic ceiling” formulation modestly reduce accessibility and precision.
“may offer new opportunities to break the therapeutic ceiling in IBD”
The review engages antioxidant trial failures, opposing HIF effects, NRF2 hormesis, and the terminated GB004 trial rather than presenting the field as settled. It also links the lack of redox-metabolomics tools to a staged implementation strategy, though comparison with non-redox precision approaches is limited.
“A tangible -omics approach to redox biology or redox metabolomics does not yet exist.”
Caveats4 of 4 checks
Unanimous assessment found no material contradictions between the paper's central claims and its discussion of mixed evidence. Aspirational framing is tempered by modal language and explicit acknowledgment of failed or undeveloped approaches.
Unanimous assessment found the funding, data-availability, and relevant interest disclosures appropriate for a narrative review. Ethics approval and preregistration are not applicable because the paper reports no new human or animal research.
Flags: 2 declared / 5 total
3 of 155 checkable references verified
157 references in manuscript 2 could not be checked — not the same as no match found
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Low2.5
The paper addresses recognized IBD needs in treatment selection, disease monitoring, and biomarker stratification, with clinicians and drug developers as identifiable users. The proposed decision tools are not yet operationally specified or available.
“matching redox-directed pharmacological interventions to individual patient phenotypes”
Some HIF-directed compounds have reached phase 1 or phase 2 testing, but one prominent phase 2 program was terminated for suggested lack of benefit. The biomarker infrastructure required for personalized redox medicine remains conceptual.
“terminated due to a suggested lack of treatment benefit”
The mechanistic evidence spans several colitis models and both major IBD categories, but the personalized framework has not been tested across clinical populations or sites. No empirical boundary-condition or sensitivity analysis is available for the proposed approach.
“concrete examples hereof do not yet exist”
The paper connects RSI research, pathway pharmacology, biomarker validation, and biomarker-stratified IBD trials into a cumulative program. Progress depends on developing and independently validating redox-metabolomics platforms and signatures.
“validation (both internally and externally) in independent cohorts should be pursued”
AI-generated, human-governed. Something look off? Contact us to request a review.